ClinicalTrials.gg
CompletedNCT01377597RVO in JapanUpdated Nov 18, 2016

Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion

A Phase 3 interventional study of ranibizumab in Retinal Vein Occlusion, sponsored by Novartis Pharmaceuticals. Completed at 8 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-18.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
47
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing ranibizumab in Retinal Vein Occlusion — none open to participants now, none under way, none of them phase 3. Ranibizumab · Retinal Vein Occlusion.

Enrollment
26th of 47
47 · median 56
Started
2011
with 4 others
Phase 3
13 of 47
none open now
Registered
17th of 47
by date
Lead sponsor
9 of 47
Novartis Pharmaceuticals

Among the 47 studies testing ranibizumab in Retinal Vein Occlusion, this one is the 26th largest by enrollment, is one of 5 that started in 2011, is one of 13 in phase 3, and was the 17th registered.

Retinal Vein Occlusion

289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.

Browse Retinal Vein Occlusion studies →

Open to participants now

None of the 47 studies testing ranibizumab in Retinal Vein Occlusion is open now. The open studies under Retinal Vein Occlusion, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 47 studies testing ranibizumab in Retinal Vein Occlusion as a file.
02

Study summary

The purpose of this study is to provide efficacy and safety data of 3 consecutive monthly intravitreal injections with 0.5 mg ranibizumab in Japanese patients with visual impairment due to macular edema secondary to retinal vein occlusion (BRVO or CRVO) to support the applicability of the phase III study results of BRAVO and CRUISE in this indication, in the Japanese ethnic patients.

03

Conditions studied

  • Retinal Vein Occlusion

Keywords

  • retinal vein occlusion
  • branch retinal vein occlusion
  • central retinal vein occlusion
  • visual impairment
  • macular edema
  • ranibizumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese patients diagnosed with visual impairment exclusively due to macular edema secondary to either branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) Diagnosis within 12 months prior to Visit 1
  • Best-corrected visual acuity (BCVA):
  • CRVO: BCVA score ≥24 and ≤73 letters ETDRS (approx. Snellen equivalent of 20/320 and 20/40) at Visit 1 and 2
  • BRVO: BCVA score ≥19 and ≤73 letters ETDRS (approx. Snellen equivalent of 20/400 and 20/40) at Visit 1 and 2

Exclusion criteria

Exclusion Criteria:

  • Pregnant or nursing women
  • History of stroke
  • Uncontrolled blood pressure
  • Active ocular infection or intraocular inflammation in either eye
  • Uncontrolled glaucoma in either eye
  • Neovascularization of the iris or neovascular glaucoma in either eye
  • Prior episode of RVO more than 12 months prior to Visit 1 in the study eye
  • Use of any systemic anti-VEGF drugs within 6 months prior to Visit 2
  • Prior treatment with any anti-angiogenic drugs within 3 months prior to Visit 2 in either eye
  • Prior panretinal laser photocoagulation within 3 months prior to Visit 2 in the study eye
  • Prior focal/grid laser photocoagulation within 4 months prior to Visit 2 in the study eye
  • Use of intra-/peri-ocular within 3 months prior to Visit 1 in the study eye
  • Use of any intra-ocular corticosteroid implants in the study eye

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    ranibizumab intravitreal injection

    Drug: ranibizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Measure: Efficacy of 3 consecutive monthly intravitreal injections with 0.5 mg ranibizumab as assessed by the mean average change in best-corrected visual acuity (BCVA) from Month 1 through Month 3 compared to baseline

    Time frame: 3 months

Secondary outcomes

  1. Measure: Efficacy of monthly ranibizumab injections as assessed by the mean BCVA change from baseline over time to Month 3, by visit

    Time frame: 3 months

  2. Measure: Efficacy of monthly ranibizumab injections as assessed by the mean change in central subfield thickness (CSFT) of the retina from baseline over time to Month 3

    Time frame: 3 months

  3. Measure: Efficacy of monthly ranibizumab injections as assessed by the proportion of patients achieving BCVA improvement of ≥1, ≥5, ≥10, ≥15, and ≥30 letters from baseline to Month 3

    Time frame: 3 months

  4. Measure: Efficacy of monthly ranibizumab injections as assessed by the proportion of patients with a BCVA loss of <15 letters from baseline to Month 3

    Time frame: 3 months

  5. Measure: Safety of monthly ranibizumab injections as assessed by the type, frequency and severity of adverse events

    Time frame: 3 months

07

Study locations

8 sites
  • Novartis Investigative Site
    Nagoya, Aichi 466-8560, Japan
  • Novartis Investigative Site
    Nagoya, Aichi 467-8602, Japan
  • Novartis Investigative Site
    Fukuoka-city, Fukuoka 812-8582, Japan
  • Novartis Investigative Site
    Kita-gun, Kagawa 761-0793, Japan
  • Novartis Investigative Site
    Suita-city, Osaka 565-0871, Japan
  • Novartis Investigative Site
    Ohtsu, Shiga 520-2192, Japan
  • Novartis Investigative Site
    Kyoto, 606-8507, Japan
  • Novartis Investigative Site
    Osaka, 545-8586, Japan
08

References and documents

Publications

  • Kamei M, Terasaki H, Yoshimura N, Shiraga F, Ogura Y, Grotzfeld AS, Pilz S, Ishibashi T. Short-term efficacy and safety of ranibizumab for macular oedema secondary to retinal vein occlusion in Japanese patients. Acta Ophthalmol. 2017 Feb;95(1):e29-e35. doi: 10.1111/aos.13196. Epub 2016 Sep 22. PubMed 27654837 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Apr 2012 and a completion of Apr 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2011
First posted
Jun 21, 2011
Start
Jun 2011
Primary completionActual
Apr 2012
CompletionActual
Apr 2012
Last update
Nov 18, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01377597
Responsible party
Sponsor
First posted
Jun 21, 2011
Start date
Jun 2011
Primary completion
Apr 2012
Completion
Apr 2012
Last update
Nov 18, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
Novartis Pharma AG
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion